Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients

References

• Teh BW, Yeoh DK, Haeusler GM, Australasian Antifungal Guidelines Steering Committee, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Intern Med J. 2021;51(Suppl 7):67–88.
   PubMedGoogle Scholar
• Maertens JA, Girmenia C, Bruggemann RJ, European Conference on Infections in Leukaemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN), et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European conference on infections in leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230.
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36(30):3043–3054.
   PubMed Web of Science ®Google Scholar
• Pbs.gov.au. 2018. Pharmaceutical Benefits Scheme (PBS) |. [online] Available at: http://www.pbs.gov.au/medicine/item/10460M. [Accessed 6 Oct. 2018].
   Google Scholar
• Pham AN, Bubalo JS, Lewis JS. 2nd. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses. 2016;59(4):226–233.
   PubMed Web of Science ®Google Scholar
• Oh J, Kang CI, Kim SH, et al. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with hematologic malignancy: therapeutic drug monitoring, efficacy, and risk factors for the suboptimal level. Mycoses. 2020;63(1):89–94.
   PubMed Web of Science ®Google Scholar
• Belling M, Kanate AS, Shillingburg A, et al. Evaluation of serum posaconazole concentrations in patients with hematological malignancies receiving posaconazole suspension compared to the Delayed-Release tablet formulation. Leuk Res Treatment. 2017;2017:1–6.
   Google Scholar
• Chau MM, Daveson K, Alffenaar JC, Australasian Antifungal Guidelines Steering Committee, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Intern Med J. 2021;51(Suppl 7):37–66.
   PubMedGoogle Scholar
• Miceli MH, Perissinotti AJ, Kauffman CA, et al. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis [research support, Non-U.S. Gov’t]. Mycoses. 2015;58(7):432–436.
   PubMed Web of Science ®Google Scholar
• Chin A, Pergam SA, Fredricks DN, et al. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob Agents Chemother. 2017;61(10):e00569–17.
   Google Scholar
• Cojutti PG, Candoni A, Lazzarotto D, et al. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies [in press]. Br J Clin Pharmacol. 2018;84(11):2544–2550.
   PubMed Web of Science ®Google Scholar
• Leclerc E, Combarel D, Uzunov M, et al. Prevention of invasive Aspergillus fungal infections with the suspension and delayed-release tablet formulations of posaconazole in patients with haematologic malignancies. Sci Rep. 2018;8(1):1681.
   PubMedGoogle Scholar
• Lenczuk D, Zinke-Cerwenka W, Greinix H, et al. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy, and tolerability. Antimicrob Agents Chemother. 2018;62(6):e02655–17.
   PubMed Web of Science ®Google Scholar
• Zhou PY, Lim TP, Tang SLS, et al. Therapeutic drug monitoring is necessary for patients receiving posaconazole tablet. J Infect. 2021;82(6):e18–e21.
   PubMed Web of Science ®Google Scholar
• Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma [multicenter study randomized controlled trial]. Clin Pharmacol Ther. 2010;88(1):115–119.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.
   PubMed Web of Science ®Google Scholar
• Tang LA, Marini BL, Benitez L, et al. Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017;72(10):2902–2905.
   PubMed Web of Science ®Google Scholar
• Pham AN, Bubalo JS, Lewis JS. Posaconazole tablet formulation at 400 milligrams daily achieves desired minimum serum concentrations in adult patients with a hematologic malignancy or stem cell transplant. Antimicrob Agents Chemother. 2016; 60(11):6945–6947.
   PubMed Web of Science ®Google Scholar
• Kraljevic M, Khanna N, Medinger M, et al. Swiss Transplant Cohort Study. Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Med Mycol. 2021 Jul 6;59(7):701–711.
   Google Scholar
• Schauwvlieghe A, Buil JB, Verweij PE, et al. High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. Mycoses. 2020;63(2):122–130.
   PubMed Web of Science ®Google Scholar
• Märtson A‐G, Veringa A, Heuvel ER, et al. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. Mycoses. 2019;62(8):698–705.
   PubMed Web of Science ®Google Scholar
• Maleki S, Corallo C, Coutsouvelis J, et al. Failure to achieve therapeutic levels with high-dose posaconazole tablets potentially due to enhanced clearance. J Oncol Pharm Pract. 2018;24(1):63–66.
   PubMed Web of Science ®Google Scholar
• Lindsay J, Ibrahim K, Sandaradura I. Posaconazole plasma concentrations during intravenous to oral tablet crossover: are variations due to distribution and metabolism rather than absorption? Biol Blood Marrow Transplant. 2016;22(3):S475–S476.
   PubMed Web of Science ®Google Scholar
• Leelawattanachai P, Montakantikul P, Nosoongnoen W, et al. Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis. TCRM. 2019;15:589–595.
   Google Scholar
• Fontana RJ, Watkins PB, Bonkovsky HL, DILIN Study Group, et al. Drug-Induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health U.S. Department of Health & Human Services. SEVERITY GRADING IN DRUG INDUCED LIVER INJURY.: LiverTox; [cited 2018 1st October]. Available from: https://livertox.nih.gov/Severity.html.
   Google Scholar
• Goedhart, J. Plots Of Differences – a Web App for the Quantitative Comparison of Unpaired Data. bioRxiv. 578575. doi:10.1101/578575
   Google Scholar
• Cornely OA, Langston A, Kartsonis N, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718–726.
   PubMed Web of Science ®Google Scholar
• Boglione-Kerrien C, Picard S, Tron C, et al. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies [observational study. J Cancer Res Clin Oncol. 2018;144(1):127–134.
   PubMed Web of Science ®Google Scholar
• Peterlin P, Chauvin C, Le Gouill S, et al. Fungal prophylaxis with a gastro-resistant posaconazole tablet for patients with hematological malignancies in the POSANANTES study. Antimicrob Agents Chemother. 2018; 62(2):e01746–17.
   PubMed Web of Science ®Google Scholar
• Cumpston A, Caddell R, Shillingburg A, et al. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob Agents Chemother. 2015;59(8):4424–4428.
   PubMed Web of Science ®Google Scholar
• Tverdek FP, Heo ST, Aitken SL, et al. Real-Life assessment of the safety and effectiveness of the new tablet and intravenous formulations of posaconazole in the prophylaxis of invasive fungal infections via analysis of 343 courses [research support, Non-U.S. Gov’t]. Antimicrob Agents Chemother. 2017;61(8):08.
   Web of Science ®Google Scholar
• Yi WM, Schoeppler KE, Jaeger J, et al. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob. 2017;16(1):60.
   PubMedGoogle Scholar
• Vanstraelen K, Prattes J, Maertens J, et al. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. Eur J Clin Pharmacol. 2016;72(8):953–963.
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Bruggemann RJ, Burger DM, et al. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis [research support, Non-U.S. Antimicrob Agents Chemother. 2014;58(11):6879–6885.
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–966.
   PubMed Web of Science ®Google Scholar
• Kraft WK, Chang PS, van Iersel ML, et al. Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother. 2014;58(7):4020–4025.
   PubMed Web of Science ®Google Scholar
• van Iersel M, Rossenu S, de Greef R, et al. A Population Pharmacokinetic Model for a Solid Oral Tablet Formulation of Posaconazole. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e02465–17.
   Google Scholar
• Wasmann RE, Smit C, van Donselaar MH, et al. Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother. 2020;75(4):1006–1013.
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56(8):4196–4201.
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers [clinical trial, phase I randomized controlled trial research support, Non-U.S. Gov’t]. J Antimicrob Chemother. 2012;67(11):2725–2730.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Lopez-Jimenez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia [clinical trial, phase I research support, Non-U.S. Gov’t]. Antimicrob Agents Chemother. 2014;58(10):5758–5765.
   PubMed Web of Science ®Google Scholar
• Stelzer D, Weber A, Ihle F, et al. Comparing azole plasma trough levels in lung transplant recipients: percentage of therapeutic levels and intrapatient variability [comparative study]. Ther Drug Monitor. 2017;39(2):93–101.
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Merelli M, Allegri L, et al. Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring. Br J Clin Pharmacol. 2019;85(1):266–269.
   PubMed Web of Science ®Google Scholar
• Danion F, Jullien V, Rouzaud C, et al. Is it time for systematic voriconazole pharmacogenomic investigation for central nervous system aspergillosis? Antimicrob Agents Chemother. 2018;62(9):e00705–18.
   PubMed Web of Science ®Google Scholar
• Wei XC, Zhao MF, Li X, et al. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Int J Antimicrob Agents. 2020;56(4):106112.
   PubMed Web of Science ®Google Scholar